🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 53 Guangzhou 40 Beijing 33 Chengdu 13 Wuhan 10
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University454 Ruijin Hospital276 Shanghai Zhongshan Hospital163 RenJi Hospital135 Children's Hospital of Fudan University84 Clear sponsor filter
Site location
Shanghai53 Guangzhou40 Beijing33 Chengdu13 Wuhan10
All 42 locations
Target enrolment
to

Trials with a site in Shanghai

53 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT07788950Head and Neck Squamous Cell Carcinomas, Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
30
Shanghai
2026-09
Not yet open
A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer
NCT07641855Castration-resistant Prostate Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
180
Beijing, Shanghai
2026-09
Not yet open
A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
NCT07729956Triple-Negative Breast Cancer (TNBC)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
436
Shanghai
2026-08
Not yet open
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid Tumors
NCT07763639Head and Neck Tumors, Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
30
Changsha, Shanghai
2026-08
Not yet open
A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan
NCT07730489Colorectal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
130
Shenyang, Shanghai
2026-08
Recruiting
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
NCT07642024Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
90
Shanghai
2026-07-24
Recruiting
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
NCT07654400Extensive-stage Small-cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
36
Shanghai
2026-07-09
Recruiting
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
NCT07502300Extensive-stage Small-cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
562
Zhengzhou, Shanghai
2026-06-15
Recruiting
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma
NCT07152405Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
490
Harbin, Shanghai
2025-09-24
Recruiting
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
NCT07054567Cervical Cancer, Endometrial Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
96
Shanghai
2025-08-21
Recruiting
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
NCT06994195Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
450
Shanghai
2025-08-04
Recruiting
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
NCT07056556Non-small Cell Lung Cancer, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
31
Shanghai
2025-07-30
Recruiting
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
NCT06962787Renal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
260
Shanghai
2025-07-28
Recruiting
A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
NCT06986785Advanced Hepatocellular Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
74
Shanghai
2025-06-24
Recruiting
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
NCT06978114Advanced Biliary Tract Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
46
Shanghai
2025-06-10
Recruiting
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
NCT06857214Systemic Lupus Erythematosus
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
84
Shanghai
2025-06-04
Recruiting
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
NCT06830889HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
1,450
Nanjing, Shanghai
2025-06-03
Recruiting
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
NCT06857175Urothelial Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
508
Shanghai
2025-03-25
Recruiting
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis
NCT06857227Rheumatoid Arthritis
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
54
Shanghai
2025-03-17
Recruiting
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
NCT06838273Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
720
Shanghai
2025-02-24
Recruiting
A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06718621Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Shanghai
2025-02-12
Active, closed
A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06423885HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
64
Shanghai
2024-12-24
Active, closed
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06668961Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
48
Shanghai
2024-11-07
Recruiting
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
NCT06612840Non-small Cell Lung Cancer, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Shanghai
2024-10-16
Recruiting
A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT06493864Breast Cancer, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
21
Shanghai
2024-08-26
Recruiting
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
NCT06503783Breast Cancer, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Harbin, Shanghai
2024-08-24
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
NCT06471205Triple-negative Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
52
Shanghai
2024-08-02
Recruiting
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
NCT06505824Small Cell Lung Cancer, Neuroendocrine Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Shanghai
2024-08-02
Recruiting
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06498986Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
40
Shanghai
2024-07-31
Recruiting
A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06469008Head and Neck Squamous Cell Carcinomas, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
21
Shanghai
2024-06-27
Active, closed
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
NCT06382142Triple-Negative Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
418
Shanghai
2024-06-21
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
NCT06437509Extensive-stage Small-cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
66
Shanghai
2024-06-13
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06437522Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
46
Shanghai
2024-06-07
Recruiting
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
NCT06405425Urothelial Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
52
Shanghai
2024-05-29
Recruiting
A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
NCT06042894Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
58
Shanghai
2023-12-12
Recruiting
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
NCT05965856Urothelial Carcinoma, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
52
Shanghai
2023-12-11
Active, closed
A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT05949606Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
95
Shanghai
2023-10-30
Recruiting
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06006169Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
186
Shanghai
2023-10-20
Active, closed
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
NCT05949619Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
14
Shanghai
2023-09-04
Recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05924750Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
130
Hefei, Beijing, Haerbin, Shenyang, Jinan, Shanghai, Chengdu, Tianjin
2023-08-02
Active, closed
A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT05880706Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
198
Shanghai
2023-07-19
Recruiting
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
NCT05803018Gynecological Malignant Tumor, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
38
Shanghai
2023-06-25
Recruiting
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
NCT05785039Urinary System Tumor, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
76
Shanghai
2023-04-20
Active, closed
A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
NCT05668858Squamous Cell Carcinoma of Head and Neck
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
70
Shanghai
2023-02-10
Recruiting
Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
NCT05631964Locally Advanced or Metastatic Digestive Tract Tumors, Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
26
Shanghai
2023-01-05
Recruiting
A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT05470348Breast Cancer, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
36
Guangzhou, Shanghai
2022-08-11
Active, closed
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
NCT05192486Diffuse Large B-cell Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
12
Shenzhen, Baoding, Luoyang, Shanghai
2022-08-10
Active, closed
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy
NCT05104775Hematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
33
Guangzhou, Guiyang, Shijiazhuang, Wuhan, Shenyang, Shanghai, Yibin
2022-02-09
Active, closed
A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC
NCT05054439Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
45
Guilin, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou
2021-12-22
Recruiting
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
NCT05194982Locally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
570
Chongqing, Guangzhou, Wuhan, Changsha, Shanghai, Taiyuan
2021-11-29
Active, closed
A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
NCT05044897Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
11
Guilin, Guiyang, Shanghai
2021-10-20
Active, closed
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
NCT04606472Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Beijing, Chongqing, Xiamen, Zhengzhou, Wuhan, Shanghai, Chengdu
2020-11-10
Active, closed
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
NCT04606433Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
47
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Tianjin, Hangzhou
2020-11-04
Rows per page Showing 1–53 of 53
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 53 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

35 of the 53 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 53 studies
PhaseStudiesRecruitingShare
Phase 2201437.7%
Phase 1171332.1%
Phase 39617%
Phase 1/2519.4%
Phase 2/3213.8%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.5335
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.